NCT06546540View on ClinicalTrials.gov

The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis

PHASE4RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

June 8, 2024

Primary Completion Date

December 10, 2025

Study Completion Date

March 30, 2026

Conditions

Systemic Sclerosis

Interventions

DRUG

Telitacicept

160mg，once weekly

Trial Locations (1)

Unknown

RECRUITING

Peking Third Hospital, Beijing

All Listed Sponsors

lead

Peking University Third Hospital

OTHER